Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Oaktree Acquisition Corp. III Life Sciences Unit (OACCU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: OACCU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 6.47% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.99 - 10.99 | Updated Date 06/14/2025 |
52 Weeks Range 9.99 - 10.99 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Unit
Company Overview
History and Background
Oaktree Acquisition Corp. III Life Sciences Unit was a special purpose acquisition company (SPAC) focused on the life sciences sector. SPACs are shell companies formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing operating company. The SPAC no longer exists independently, having completed a merger with a target company.
Core Business Areas
Leadership and Structure
Typically SPACs are led by a management team with experience in the target sector and finance. The structure involves the management team, a board of directors, and investors who purchase shares in the IPO.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
SPACs operate within the broader financial market and their success is tied to the target industry they are focused on. The life sciences industry is characterized by high growth potential, innovation, and regulatory complexities.
Positioning
Oaktree Acquisition Corp. III Life Sciences Unit's positioning depended on the quality and potential of the target company it sought to acquire. The Oaktree brand likely lent some credibility and access to deals.
Total Addressable Market (TAM)
The TAM for life sciences is vast and constantly evolving, encompassing pharmaceuticals, biotechnology, medical devices, and healthcare services. Oaktree's positioning relative to the TAM depended entirely on the market share and growth of its target acquisition.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Strong Financial Backing (from Oaktree)
- Access to Deal Flow
- Potential for High Returns
Weaknesses
- Time Constraints (SPACs typically have a limited time to complete an acquisition)
- Deal Risk (Finding a suitable target is challenging)
- Dilution of Shareholder Value (SPACs often issue shares to fund acquisitions)
- Regulatory Risks
- Dependence on target companies' performance
Opportunities
- Growing Demand for Life Sciences Products and Services
- Increasing Investment in Biotechnology and Pharmaceuticals
- Consolidation in the Life Sciences Industry
- Technological Advancements in Healthcare
Threats
- Increased Competition from Other SPACs and Private Equity Firms
- Regulatory Changes and Healthcare Reform
- Economic Downturn
- Failure to Find a Suitable Acquisition Target
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape for SPACs involves other SPACs, private equity firms, and strategic acquirers looking to invest in the life sciences sector.
Growth Trajectory and Initiatives
Historical Growth: Growth trajectory is not applicable to a SPAC prior to an acquisition.
Future Projections: Future projections depended entirely on the potential of the target acquisition.
Recent Initiatives: Recent initiatives would have involved scouting potential acquisition targets.
Summary
Oaktree Acquisition Corp. III Life Sciences Unit was a SPAC aiming to acquire a promising life sciences company. Its strength lay in its experienced management and Oaktree's backing. The success hinged on finding a suitable target and integrating it effectively. Potential threats included competition from other SPACs and adverse market conditions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Press Releases (historical)
- Financial News Outlets (historical)
Disclaimers:
This analysis is based on publicly available information and historical data. The information is provided for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Unit
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-10-24 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.